Q-Med's Durolane Knee Therapy, DePuy's CoMplete Hip Go To Panel
This article was originally published in The Gray Sheet
Executive SummaryFDA's Orthopedic and Rehabilitation Devices panel will meet Aug. 19 to assess Q-Med's PMA application for its Durolane single-injection, hyaluronic acid-based treatment for knee osteoarthritis
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.